©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
World J Gastroenterol. Mar 7, 2026; 32(9): 116223
Published online Mar 7, 2026. doi: 10.3748/wjg.v32.i9.116223
Published online Mar 7, 2026. doi: 10.3748/wjg.v32.i9.116223
Advances in non-invasive biomarkers for pediatric inflammatory bowel disease diagnosis
Li Zheng, Department of Anesthesia Recovery Room, The First Hospital of Jilin University, Changchun 130021, Jilin Province, China
Han-Run Wang, Department of Gastric and Colorectal Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun 130021, Jilin Province, China
Yan Jiao, Ya-Hui Liu, Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun 130021, Jilin Province, China
Co-corresponding authors: Yan Jiao and Ya-Hui Liu.
Author contributions: Zheng L and Wang HR contributed to the conception of the editorial and the acquisition and interpretation of relevant literature; Jiao Y and Liu YH contributed to the critical intellectual revision of the manuscript and provided overall academic supervision; Zheng L drafted the initial manuscript; all authors reviewed and approved the final version of the manuscript.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Corresponding author: Ya-Hui Liu, MD, Doctor, Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, The First Hospital of Jilin University, No. 1 Xinmin Street, Changchun 130021, Jilin Province, China. yahui@jlu.edu.cn
Received: November 6, 2025
Revised: December 14, 2025
Accepted: January 6, 2026
Published online: March 7, 2026
Processing time: 114 Days and 2.5 Hours
Revised: December 14, 2025
Accepted: January 6, 2026
Published online: March 7, 2026
Processing time: 114 Days and 2.5 Hours
Core Tip
Core Tip: Biomarkers and genetic testing are transforming the diagnosis and management of pediatric inflammatory bowel disease (IBD), offering non-invasive alternatives to traditional invasive diagnostic methods. Fecal calprotectin and genetic markers show promise in accurately distinguishing Crohn’s disease from ulcerative colitis, while multi-omic approaches and machine learning models enhance predictive capabilities for disease progression and therapy responses, supporting precision medicine in pediatric IBD.